Coloplast’s Post

As a proud member of Coloplast’s Customer Activation team, I’m thrilled to share a glimpse into the future of personal healthcare. We’re not just launching products; we’re elevating experiences and expectations with all of our offerings. 🔥 We Aim High - At Coloplast, ‘aiming high’ isn’t just a Leadership Promise; it’s our practice. With all our activities, we’re reaching for unprecedented levels of quality, comfort, and design. Each product is a reflection of our commitment to excellence and our relentless pursuit of innovation and in making life easier for people with intimate healthcare needs. 🚀 Being at the heart, in Coloplast Business Centre - CPBC, is not just exciting; it’s transformative. It’s where passion meets purpose, where we see the tangible impact of our work on people’s lives. And as we aim high, we’re not just reaching our goals; we’re setting new ones. 💙 #Coloplast #WeAimHigh #BrandAdvocates #CPBC #CareersThatMakeADifference #MakingLifeEasier

I love my job! I've been at Teva for 8 years and now more than ever, I love my job! I am working with smart people. I'm doing cool stuff that's making an impact, and I'm having fun! And we are winning! One day at a time, quarter by quarter, we are making it happen! Teva is coming in hot! It starts with our purpose: we are all in for better health. And a sound strategy to keep us focused and moving forward. Discover the four key pillars behind Teva’s growth, from stepping up innovation to find new treatments for unmet medical need to delivering affordable, high-quality generics medicines to people around the world. Our direction is clear, and momentum is building, in service to people living with chronic medical conditions, customers and healthcare systems. Watch us go. Discover more: https://lnkd.in/eqDc57m2 #PivotToGrowth #WeAreAllInForBetterHealth

When good business and effective healthcare produce economic success, that’s a true win-win.

The 𝐈𝐧𝐝𝐨𝐧𝐞𝐬𝐢𝐚 𝐓𝐢𝐬𝐬𝐮𝐞 𝐄𝐧𝐠𝐢𝐧𝐞𝐞𝐫𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭, valued at 𝐔𝐒𝐃 𝟏𝟓𝟏.𝟐𝟎 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐢𝐧 𝟐𝟎𝟐𝟑 is set to soar to 𝐔𝐒𝐃 𝟓𝟏𝟔.𝟐𝟗 𝐦𝐢𝐥𝐥𝐢𝐨𝐧 𝐛𝐲 𝟐𝟎𝟑𝟐, growing at a remarkable 𝐂𝐀𝐆𝐑 𝐨𝐟 𝟏𝟒.𝟔𝟐% 𝐟𝐫𝐨𝐦 𝟐𝟎𝟐𝟒 𝐭𝐨 𝟐𝟎𝟑𝟐. This rapid growth highlights Indonesia's expanding capabilities and investments in biomedical innovations. As advancements in tissue engineering continue, they hold promising potential for healthcare improvements and economic growth in the region. Stay tuned for more updates in this dynamic field. 𝐅𝐨𝐫 𝐦𝐞𝐝𝐢𝐚 𝐢𝐧𝐪𝐮𝐢𝐫𝐢𝐞𝐬 𝐨𝐫 𝐟𝐮𝐫𝐭𝐡𝐞𝐫 𝐢𝐧𝐟𝐨𝐫𝐦𝐚𝐭𝐢𝐨𝐧:- https://lnkd.in/ggczNiEa 𝐓𝐨𝐩 𝐏𝐥𝐚𝐲𝐞𝐫𝐬 𝐢𝐧 𝐭𝐡𝐞 𝐈𝐧𝐝𝐨𝐧𝐞𝐬𝐢𝐚 𝐓𝐢𝐬𝐬𝐮𝐞 𝐄𝐧𝐠𝐢𝐧𝐞𝐞𝐫𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 3M Medtronic Stryker AbbVie Smith+Nephew Other Prominent Players #TissueEngineering #Indonesia #HealthcareInnovation #MarketGrowth #BiomedicalResearch

🎉 Exciting News! 🎉 Unlisted PharmEasy shares now available at just Rs 12 with a minimum quantity of 25k! Don't miss this opportunity! PharmEasy's CEO is optimistic about the company's future, aiming for an IPO soon if our strong performance continues. Check out website at pharmeasy.in for more details. 🌟 Big Investment Alert! 🌟 The renowned Manipal Group is showing interest in investing Rs 1,000 crore for an 18% stake in API Holdings, PharmEasy's parent company. This, along with Rs 1,500 crore from existing investors, is a potential game-changer for PharmEasy! 💼 Thriving After Thyrocare Acquisition 💼 Our acquisition of Thyrocare Technologies in 2021 was a major boost. Despite the added debt, we're stronger than ever and ready for big things! DM if you are interested Disclaimer: Investment in unlisted PharmEasy shares involves risks. Please conduct your own research

This is incredible - the maker of Ozempic, Novo Nordisk, is effectively driving the entire economy of Denmark: "Nearly 1 out of every 5 Danish jobs created last year was at Novo. And that's just directly. If you also include the jobs that Novo has created indirectly — like, for example, at its suppliers, or from all the newly wealthy Novo employees spending their money at shops and restaurants — nearly half of all private-sector nonfarm jobs created in Denmark can be traced back to Novo." via Planet Money https://lnkd.in/ePGmV4eM

Link Intime India Pvt. Ltd. was felicitated at the listing ceremony of Indegene 𝗟𝗶𝗺𝗶𝘁𝗲𝗱 that took place at NSE India on 13th May 2024 Seen here is Mr. Haresh Hinduja – Head Primary, Mr. Dhawal Adalja – Vice President Primary Market & Ms. Neha Pereira – Associate Primary Market receiving the memento from Dr. Sanjay Parikh - Executive Director and Executive Vice President, Dr. Rajesh Nair - Non-Executive Director and Mr. Manish Gupta - Chairman, Executive Director and Chief Executive Officer 𝗖𝗼𝗺𝗽𝗮𝗻𝘆 𝗜𝗻𝗳𝗼𝗿𝗺𝗮𝘁𝗶𝗼𝗻 Indegene Limited is a digital-first, life sciences commercialization company. They help biopharmaceutical, emerging biotech and medical device companies develop products, get them to the market, and grow their impact through the life cycle in a more effective, efficient, and modern way. They bring together healthcare domain expertise, fit-for-purpose technology, and an agile operating model to provide a diverse range of solutions. Their aim to deliver, amongst other outcomes, a personalized, scalable and omnichannel experience for patients and physicians. The offer (excluding Anchor Investor Portion) received > 𝟯𝟰.𝟱𝟬 𝗹𝗮𝗰𝘀 bids resulting in 𝟳𝟬.𝟰𝟮 times subscription. #LifeatlinkIntime #IPO2024 #capitalmarkets #shareholders #nseindia #indianstockmarket #stockmarketinvesting

Cipla, a leading #pharmaceuticalcompany, has announced its plans to further invest up to Rs 26 crore in Achira Labs Pvt. Ltd. through Optionally Convertible Preference Shares. This investment, divided into four tranches, is contingent upon the achievement of #specific milestones. Achira Labs Pvt. Ltd. specializes in the development and commercialization of point-of-care medical test kits in India, addressing critical healthcare needs. With this investment, Cipla aims to strengthen its support for Achira's innovative solutions in the #medical #diagnostics space. Following the completion of the first tranche of investment, Cipla will hold approximately 27.27% of the total voting rights in Achira. This strategic move underscores Cipla's commitment to fostering innovation and expanding its footprint in the #healthcare sector. The investment signifies a significant step towards advancing healthcare accessibility and affordability, aligning with Cipla's mission of 'Caring for Life.' As the #collaboration progresses, it is expected to drive innovation, enhance medical diagnostics capabilities, and ultimately, improve patient outcomes. https://lnkd.in/gSacj9Vp #News #Medlr #Healthnews #Healthcare #Health

they are humans but to greedy selfish egoistic and money minded. medical colleges like kasturba ramaiah etc. crores fees private nursing homes and corporate hospitals so costly. they run hospitals as money making profit entity drugs manufacturers so costly they never in website mention cost of inputs to each drug. worst is the useless tests in the private labs etc. google news For the year ended Jun 2024, Narayana Hrudayalaya Ltd had posted a profit of Rs 201.49 crore on a total income of Rs 1,364.44 crore. Dr. Reddy's Laboratories reported the following financial results for the quarter ending March 2024: Net profit: ₹1,307 crore, a 36% increase year-on-year Revenue: ₹7,083 crore, a 12.5% increase from Q4FY23 EBITDA: ₹1,872 crore, a nearly 15% increase year-on-year Margin: 26.4%, up from 25.9% a year ago According to Tracxn, Manipal Health Enterprises' revenue in FY22 stood at Rs 4,084 crore and its profit stood at Rs 541 crore. As per Statista, Manipal Hospitals had the highest private equity investment of about USD 286 million in 2021 in the healthcare sector.8 Apr 2023 Apollo Hospitals Enterprise (AHEL) on Tuesday reported an 83 per cent rise in net profit during the first quarter of the financial year 2024-25 to Rs 305 crore, up from Rs 167 crore during the April to June quarter of 2023-24.13 Aug 2024 Fortis Healthcare has reported a 40% increase in its consolidated profit after tax to ₹174 crore for the first quarter ended June 30, 2024 (Q1FY25) aided by strong performance in the hospital business. The healthcare major had reported a profit after tax (PAT) of ₹124 crore in the April-June quarter of last fiscal.8 Aug 2024 D Y Patil Medical College, Navi Mumbai This college offers India's most expensive medical degree, with an MBBS program that costs over Rs 1.35 crore for the four-and-a-half-year course. The annual fee is Rs 30.5 lakh, which includes hostel charges, and there's also a one-time university fee of Rs 2.84 lakh. https://lnkd.in/gSGbNPuE https://lnkd.in/guZCVUwH Apollo Hospitals Manipal Hospitals (MHEPL) Fortis Healthcare DY Patil University Kasturba Medical College, Manipal

Nord Pacific Medical to bring regulatory and market access services to East Asia